Index

Note: Page numbers of article titles are in boldface type.

A

Adherence, medication. See Medication adherence.
Adhesion molecules, in arterial wall stiffness, 610
Adiponectin deficiency, atherosclerosis in, 683–684
Adipose tissue. See also Obesity.
    angiotensinogen in, 571
African American Study of Kidney Disease (AASK), 699–701
Aging
    arterial. See Arteries, aging of.
    diastolic dysfunction in, 647–664
    heart failure prevention in, 671
    hypertension prevalence in, 650
Alcohol intake, blood pressure and, 739
Aldosterone
    action of, 571, 574
    antagonists of, for hypertension, 706
Aliskiren, for hypertension, 561
    in chronic kidney disease, 706
    in obesity, 742
Alkoxy radicals, structure of, 621
Alpha-1 adrenergic blockers, for hypertension, in obesity, 741, 743
Alpha-2 agonists, centrally acting, for hypertension, in obesity, 741, 743
Alpha blockers, for hypertension, in chronic kidney disease, 708
Amlodipine, for hypertension, 689
    in cardiovascular disease prevention, 615
    in chronic kidney disease, 700, 707
    in diastolic dysfunction, 656, 658–659
    metabolic effects of, 577
Angiography, in renovascular hypertension, 728–729
Angioplasty and Stenting in Renal Atherosclerotic Lesions trial, 727
Angiotensin (1-7), action of, 562
Angiotensin II. See also Renin-angiotensin-aldosterone system.
    in arterial aging, 592–597
    intracellular, 563
    reactive oxygen species and, 573, 627–628
    receptors for, 561–562
    vascular disease due to, 559–563
Angiotensin II-receptor blockers
    action of, 560–561
    for cardiometabolic syndrome, 575–576
    for diastolic dysfunction, 657
Angiotensin (continued)

for hypertension
  in chronic kidney disease, 701, 705–706
  in heart failure prevention, 671
  in obesity, 741–742
  renovascular, 724

Angiotensin type 1 receptor. See AT-1 receptor.

Angiotensin-converting enzyme, ACE2 homolog of, 562

Angiotensin-converting enzyme inhibitors, for hypertension, 689–690
  for cardiovascular disease prevention, 615
  in chronic kidney disease, 701, 703–705
  in diastolic dysfunction, 656–657
  in heart failure prevention, 671
  in obesity, 741–742
  renovascular, 723–724
  with cardiometabolic syndrome, 575–576

Anglo-Scandinavian Cardiac Outcomes Trial, 615, 706

Annexin, in left ventricular hypertrophy, 643

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),
  576, 658, 671, 699, 704–705, 743

Antihypertensive drugs. See Hypertension, treatment of.

Antiobesity agents, 744

Antioxidants, 623

Aorta
  aging of
    angiotensin II signaling in, 592–597
    macroscopic structure of, 584, 586
    microscopic structure of, 584–585, 587–588
  hemodynamics of, alterations for risk reduction, 614–615
  hypertension effects on, 530
  pulse pressure in
    cardiovascular disease risk and, 611–615
    diffusion, 609–611
    factors affecting, 606–609
    systolic blood pressure in, 606–609
    weakness of, in Marfan syndrome, 562–563

Apoptosis, of cardiomyocytes, 639–641, 667

Appropriate Blood Pressure Control in Diabetes (ABCD) trial, 699

Arrhythmias, 545–546, 658

Arteries
  aging of, 583–604
    angiotensin II signaling in, 592–597
    aorta, 584–588, 592–596
    arterial blood pressure determinants in, 597–598
    calpain-1 in, 594
    compliance in, 591
    endothelial function and, 589–590, 598–599
    exaggerated, 598–600
    hypertension and, 598–600
    macroscopic structure in, 584, 586
    vmatrix metalloproteinases in, 595
mechanisms of, 609–611
microscopic structure in, 584–588, 592
monocyte chemotactic protein-1 in, 596
pulse wave reflections in, 607–608
reflected pulse wave evaluation of, 591–592
stiffness in, 591–592, 599, 653, 656
transforming growth factor-beta 1 in, 595–596
ventricular coupling with, 599–600
large. See Aorta; Large arteries.
remodeling of, 608–609
wall of, pulse pressure and, 609–611
Arterioles, high resistance, 607
AT-1 receptor, 561–563
  angiotensin II interactions with, 571
  in arterial aging, 592–593
AT-1 receptor antagonists, for hypertensive heart disease, 643
Atenolol, for hypertension
  in cardiovascular disease prevention, 615
  in chronic kidney disease, 708
  in obesity, 743
Atherosclerosis
  coronary, myocardial ischemia in, 683–684
  formation of
    angiotensin II in, 559–563
    oxidized low-density lipoprotein in, 562
  prevention of, 555
  renovascular hypertension in, 718, 721, 725–727
  risk for, 547–549
  T lymphocytes in, 629–630
Atrial natriuretic peptide, in obesity, 548
Atrium
  enlargement of, in hypertension, 652
  volume of, measurement of, 656
Autophagy, of cardiomyocytes, 639–641
Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH), 577, 656–657, 707
B
Baroreflex, reactive oxygen species effects on, 628
Benazepril, for hypertension, 577, 656
Benidipine, for hypertension, 689
Bergamo Nephrologic Diabetes Complications Trial, 707–708
Beta blockers, for hypertension
  diabetogenic action of, 576–577
  in chronic kidney disease, 708
  in heart failure prevention, 671
  in obesity, 741, 743
  meta-analysis of, 535–536
Biomarkers
  for hypertension, 536
  for left ventricular hypertrophy, 643
Bisoprolol, for heart failure prevention, 671–672
Brachial pulse pressure, 611–612
Bradykinin receptor, AT-1 receptor interactions with, 562
Brain, reactive oxygen species in, 626–628
Brain natriuretic peptide
  in hypertensive heart disease, 668
  in obesity, 548
Bundle branch blocks, 546

C
Calcium channel blockers, for hypertension, 689, 742–743
  in cardiovascular disease prevention, 615
  in chronic kidney disease, 707–708
  in obesity, 741
  meta-analysis of, 535–536
Calpain-1, in arterial aging, 594
Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity study (CHARM), 576, 657, 671, 673
Captopril, for hypertension
  in chronic kidney disease, 700
  in heart failure prevention, 673
Captopril Nephropathy Trial, 703–704
Captopril Prevention Project, 575–576
Captopril renography, in renovascular hypertension, 728
Cardiac catheterization, in diastolic dysfunction, 654
Cardiac failure. See Heart failure.
Cardiac Insufficiency Bisoprolol Study (CIBIS), 672
Cardiometabolic syndrome
  angiotensin II-receptor blockers for, 575–576
  oxidative stress in, 572–575
  renin angiotensin aldosterone system in, 571
  sympathetic nervous system activation in, 570
Cardiomyocytes
  cytoskeletal proteins of, diastolic function and, 651
  hypertrophy of, in hypertensive heart disease, 638–639
  in remodeling, 639–641, 667
  obesity effects on, 735
Cardiotrophin-1, in cardiomyocyte hypertrophy, 642
Cardiovascular disease
  heart failure in. See Heart failure.
  hypertensive. See Hypertensive heart disease.
  in aging, 583–604
  in obesity, 734–735
  J-curve controversy and, 544–545
  left ventricular hypertrophy in. See Left ventricular hypertrophy.
  prevention of, 555, 576
  risk for, 543, 547–548
    global assessment instrument for, 550–551
    preventive implications of, 554–555
    pulsatile hemodynamics and, 611–615
Cardiovascular Health Study, 666
Cardiovascular Outcomes for Renal Atherosclerotic Lesions, 717–718
Carvedilol, for hypertension
  in chronic kidney disease, 708
  in heart failure prevention, 671–672, 674
  in obesity, 743
Central nervous system, reactive oxygen species in, 626–628
Central pulse pressure, 613–614
Chlorthalidone, for hypertension
  in chronic kidney disease, 707
  in diastolic dysfunction, 658
  in heart failure prevention, 671
Circumventricular organ, reactive oxygen species effects on, 627
Clonidine, for hypertension, in obesity, 743
Cohort Study of Medication Adherence in Older Adults (CoSMO), 753–769
Collagen fibers
  hypertension effects on, 650–651
  in aging arteries, 592
  in myocardial remodeling, 640–641
 Compliance, assessment of, in diastolic dysfunction, 653–654
Computed tomography angiography, in renovascular hypertension, 729
Conduit Artery Function Evaluation (CAFE), 615
Contractility, in myocardial oxygen demand, 681–682
COOPERATE trial, 706
Coronary arteries, blood flow in, myocardial oxygen supply from, 682–683
Coronary flow reserve, in myocardial ischemia, 687
Coronary heart disease
  central pulse pressure and, 613–614
  electrocardiography in, 545–546
  myocardial ischemia in, 683–684
  risk for, 547
Cyclic mechanical forces, on arteries, 609
Cytochrome C, in cardiomyocyte apoptosis, 640
Cytokines, in extracellular matrix, 650–651
Cytoskeleton, hypertension effects on, 651

D
Diabetes mellitus
  angiotensin blockers in, 575–576
  nephropathy in, 699
Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication, 576
Diastolic dysfunction, heart failure in, 647–664
Dietary Approaches to Stop Hypertension (DASH) diet, 703, 737–738
Dietary Intervention Study in Hypertension, 738
Diuretics, for hypertension, 742
  cardiovascular-renal damage due to, 535
  diabetogenic action of, 576–577
  in chronic kidney disease, 706–707
  in obesity, 741
Doppler ultrasonography
  in diastolic dysfunction, 654–655
  in renovascular hypertension, 727–728
Doxazosin, for hypertension
  in diastolic dysfunction, 658
  in obesity, 743

E
Echocardiography
  in diastolic dysfunction, 654, 656
  in hypertensive heart disease, 667–668
  in myocardial ischemia, 687
Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients with Mild-to-Moderate Hypertension study, 659
Elastin, in aging arteries, 592
Elderly persons. See Older adults.
Electrocardiography, 545–546
  in myocardial ischemia, 686
  in obesity, 735
Enalapril
  for heart failure prevention, 671–672
  for hypertension, 689
End diastolic pressure, in diastolic dysfunction, 653–654
Endothelial cells
  dysfunction of
    diastolic dysfunction in, 651–652
    myocardial ischemia in, 685
    renovascular hypertension in, 721
  in arterial aging, 598–599
  reactive oxygen species produced in, 572
Endothelin, oxidative stress due to, 574–575
Endurance training, for diastolic dysfunction, 656
Epicardial arteries, myocardial oxygen supply from, 682–683
Epidermal growth factor receptor, AT-1 receptor interactions with, 562
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), 576, 673–674
European Working Party on High Blood Pressure in the Elderly trial, 611
Exercise
  for diastolic dysfunction, 656
  for obesity, 739
Exercise electrocardiography, in myocardial ischemia, 686
EXforge Aggressive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction trial, 658
Extracellular matrix
  hypertension effects on, 650–652
  remodeling of, 608–609

F
Felodipine, for hypertension, 689, 744
Fibrillin defects, transforming growth factor excess and, 562–563
Fibromuscular dysplasia, of renal arteries, renovascular hypertension in, 719–721, 725–727
Fibrosis
  myocardial, 640–641
  perivascular, 685
Flow propagation velocity, in diastolic dysfunction, 655
Framingham Study, 541–555
Free fatty acids, in obesity, 736

G
Genetic factors
  in hypertension, 528–529
  in left ventricular hypertrophy, 641–642
Global risk assessment instrument, 549–552
Glomerular disease, in obesity, 735

H
Heart
  hypertension effects on, 529–530
  obesity effects on, 734–735
Heart disease. See also Cardiovascular disease; Heart failure; Left ventricular hypertrophy.
  hypertensive, 637–645
Heart failure, 665–680
  diagnosis of, 667–669
  diastolic dysfunction in, 647–664
    assessment of, 653–656
    epidemiology of, 648
    pathophysiology of, 649–653
    physiology of, 648–649
    treatment of, 656–659
  with preserved ejection fraction, 647–659
  epidemiology of, 665–666
  in obesity, 735
  pathophysiology of, 666–667
  prevention of, 668, 670–671
  risk factors for, 666
  treatment of, 671–675
Heart Outcomes Prevention Evaluation (HOPE), 575, 657
Heart rate, in myocardial oxygen demand, 681–682
Hemodynamic effects, of obesity, 735–736
Hydrochlorothiazide, for hypertension, 742
  diabetogenic action of, 577
  in chronic kidney disease, 707
  in obesity, 742, 744
Hydrogen peroxide
  in hypertension, vasculature and, 628
  structure of, 621
Hydroxyl radical, structure of, 621
Hypertension
  arterial aging in, 583–604, 607–608, 653, 656
  classification of, 549–550
Hypertension (continued)
comorbid conditions with, 548
diastolic dysfunction in, 647–664
epidemiology of, 650
genetic factors in, 528–529
heart disease in. See Heart disease.
heart failure in, 647–680, 735
in chronic kidney disease, 697–715
large arteries and, 605–619
myocardial ischemia in, 681–695
obesity and. See Obesity.
oxidative stress in, 621–635
pathophysiology of, 527–540. See also Renin-angiotensin-aldosterone system.
prevention of, 553–555
progression to, 552–553
renovascular, 717–732
risk factors for, 541–558
systolic. See Systolic hypertension.
target organs in. See Heart; Kidney; Large arteries.
treatment of
  global risk assessment for, 549–552
  in cardiovascular disease prevention, 614–615
  in diastolic dysfunction, 656–659
  in heart failure prevention, 670
  in myocardial ischemia, 688–690
  in target organ protection, 559–567
  medication adherence in, 763–769
  target blood pressure for, 689
unresolved problems in, 527–540
Hypertension in the Very Elderly Trial (HYVET), 671
Hypertension Obesity Sibutramine study (HOS), 744
Hypertensive heart disease, 637–645, 665–680
detection of, 641–642
diagnosis of, 642–643, 667–669
epidemiology of, 665–666
pathophysiology of, 638–641, 666–667
treatment of, 643–644, 670–675
Hypochlorous acid, structure of, 621

I
Indapamide, for hypertension, 615, 671
Inflammation, reactive oxygen species in, 629–630
Inflammatory cells, in aging arteries, 584–585
Insulin
  action of, in kidney, 570
  resistance to. See also Cardiometabolic syndrome.
    in obesity, 734–735
Integrins, in arterial wall stiffness, 610
Intima, of aging arteries, 584–585, 587
Intra-arterial angiography, in renovascular hypertension, 729
Intracrines, angiotensin II as, 563
Irbesartan, for hypertension, 742
Irbesartan in Diabetic Nephropathy Trial (IDNT), 700
Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE), 657
Isovolumetric ventricular relaxation, assessment of, in diastolic dysfunction, 653–656

J
J-curve controversy, 544–545

K
Kidney
chronic disease of, hypertension in, 697–715
   blood pressure goals for, 697–702
   epidemiology of, 697
   proteinuria in, 698–702
   pulse wave velocity in, 612–613
   treatment of, 614–615, 699–708
hypertension effects on, 530–531
obesity effects on, 735–736
reactive oxygen species effects on, 624–626
renal artery stenosis in, 717–732
sodium handling in, 570

L
Large arteries. See also Aorta.
   hemodynamics of, alterations for risk reduction, 614–615
   hypertension effects on, 530
   pulse pressure in
      cardiovascular disease risk and, 611–615
      diffusion, 609–611
      factors affecting, 606–609
   systolic blood pressure in, factors affecting, 606–609
Left Ventricular Dysfunction trial, 671
Left ventricular hypertrophy, 529–530, 545
   diagnosis of, 642–643
   early detection of, 641–642
   genetic factors in, 641–642
   heart failure in, 667–675
   in obesity, 735
   myocardial remodeling in, 652–653
   pathophysiology of, 541
   pulsatile-components index in, 611
   reference limits for, 669
   treatment of, 643–644, 671–676
Leptin
   elevated, sympathetic nervous system activation in, 570
   obesity and, 735–736
Lifestyle changes
   for heart failure prevention, 668, 670
   for hypertension, in chronic kidney disease, 703
Lifestyle (continued)
  for myocardial ischemia, 688–689
  for obesity, 736–739
Lipid peroxy radical, structure of, 621
Lisinopril, for hypertension, 658, 742
Losartan, for hypertension
  in chronic kidney disease, 700
  in diastolic dysfunction, 659
  in hypertensive heart disease, 643
Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE), 576, 657, 670
LOX-1 receptor, 562

M
Magnetic resonance angiography, in renovascular hypertension, 728–729
Magnetic resonance imaging
  in left ventricular hypertrophy, 642
  in myocardial ischemia, 686–687
Marfan syndrome, vascular pathology in, 562–563
Matrix metalloproteinases, in arterial aging, 595
Medial hypertrophy, myocardial ischemia in, 684–685
Medication adherence, in older adults, 753–769
Metabolic syndrome. See Cardiometabolic syndrome.
Metoprolol, for hypertension
  in chronic kidney disease, 700
  in heart failure prevention, 671–672, 674
  in obesity, 743
Metoprolol CR/XL Randomises Intervention Trial in Congestive Heart Failure (MERIT-HF), 672, 674
Microalbuminuria, in chronic kidney disease, 698–702
Micromanometer catheter, in diastolic dysfunction, 654
Mineralocorticoid receptor blockers, for cardiometabolic syndrome, 576
Mitochondrial respiratory chain, in reactive oxygen species production, 572–573
Modification of Diet in Renal Disease (MDRD) Study, 699, 701
Multiple Risk Factor Intervention Trial (MRFIT), 543
Myocardial contract echocardiography, in myocardial ischemia, 686
Myocardial infarction, unrecognized, 546–547
Myocardial ischemia, 691–695
  asymptomatic, 684
  investigation of, 686–688
  mechanisms of, 683–685
  pathophysiology of, 681–683
  treatment of, 688–690
Myocardium
  fibrosis of, 640–641
  remodeling of, in hypertensive heart disease, 639–641

N
Natriuretic peptides, in obesity, 548
Nebivolol
for heart failure prevention, 671–672, 674
for hypertension, 689
in chronic kidney disease, 708
in obesity, 743
Necrosis, of cardiomyocytes, 639–641
Nicotinamide adenine dinucleotide phosphate oxidase complex
in aging arteries, 589
in reactive oxygen species production, 572–574, 622, 624–625, 627–630
Nifedipine, for hypertension, in chronic kidney disease, 707
Nitric oxide
chemistry of, 621
in aging arteries, 589
in kidney, 625
Nitric oxide synthase
action of, 622
in kidney, 625–626
in reactive oxygen species production, 572–573
Nitrogen dioxide, chemistry of, 621
Nitrosonium cation, chemistry of, 621
Nucleus tractus solitarii, reactive oxygen species effects on, 627

O

Obesity, 733–751
adipose tissue in, angiotensinogen in, 571
epidemiology of, 733
hypertension in, 531–532, 553
cardiac effects of, 734–735
hemodynamic effects of, 735–736
mechanical effects of, 735–736
renal effects of, 735–736
treatment of, 736–744
vascular adaptations in, 734–735
leptin elevation in, 570
natriuretic peptide levels in, 548
Obstructive sleep apnea, in obesity, 744
Older adults
arterial aging in. See Arteries, aging of.
diastolic dysfunction in, 647–664
heart failure prevention in, 671
hypertension prevalence in, 650
medication adherence in, 753–769
Oxidative stress. See also Reactive oxygen species.
in insulin resistance, 572–575
Oxygen demand and supply, in myocardial ischemia, 681–683

P

Perindopril, for hypertension, 615
Perindopril in Elderly People with Chronic Heart Failure trial (PEP-CHF), 657
Perivascular fibrosis, myocardial ischemia in, 685
Peroxyxynitrinate, in insulin resistance, 573
Peroxyxynitrite, structure of, 621
Positron emission tomography
  in left ventricular hypertrophy, 643
  in myocardial ischemia, 687
Prearterioles, myocardial oxygen supply from, 683
Precapillary arterioles, myocardial oxygen supply from, 683
Prehypertension, 543–544
Prorenin receptor, 560–561
Proteinuria, in chronic kidney disease, 698–702
Pulmonary venous flow Doppler studies, in diastolic dysfunction, 655
Pulsatile-components index, 611
Pulse pressure
  brachial, 611–612
  cardiovascular disease risk and, 611–615
  central, 613–614
  diffusion of, 609–611
  factors affecting, 606–609
  variation of, 609–611
  widened, 554–555
Pulse wave(s), in arterial aging, 591–592
Pulse wave velocity, in systolic hypertension, 605, 607–608, 612–613, 615
Pulsed-wave tissue Doppler imaging, in diastolic dysfunction, 655

R
Rac-1 protein, in hypertension, 627
Ramipril
  for cardiometabolic syndrome, 575–576
  for cardiovascular disease prevention, 575–576
  for diastolic dysfunction, 657
  for hypertension
    in chronic kidney disease, 700–701
    in obesity, 744
Ramipril Efficacy in Nephropathy (REIN) trial, 701
Randomized Aldacton Evaluation Study (RALES), 576, 673–674
Reactive nitrogen species, 621
Reactive oxygen species, 621–635
  degradation of, 623
  functions of, 621–623
  in hypertension, 623–630
    central nervous system and, 626–628
    inflammation and, 629–630
    kidney and, 624–626
    vasculature and, 628
  in insulin resistance, 572–575
  pathogenicity of, 623
  types of, 621
REASON study, 615
Reduction of Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), 700, 705–706

Renal arteries
  diagnostic evaluation of, 727–729
  revascularization of, 725–727

Renin inhibitors, for hypertension, in obesity, 741–742

Renin-angiotensin-aldosterone system, 569–582
  AT-1 receptor in, 561–562
    blockade of. See Angiotensin-converting enzyme inhibitors; Angiotensin II-receptor blockers.
  chronic activation of, diastolic dysfunction in, 652
  description of, 571
  dysfunction of, vascular disease in, 559–560
  function of, 571
    in arterial aging, 592–597
    in insulin resistance, 574–575
    in reactive oxygen species generation, 572–575
    in sodium handling, 570
    intracrine, 563
    pathologic effects of, 571
    (pro)renin receptor in, 560–561
    sympathetic nervous system interactions with, 570
    transforming growth factor and, 562–563

Renography, captopril, in renovascular hypertension, 728

Renovascular hypertension, 717–732
  clinical features of, 719–722
  diagnosis of, 727–729
  epidemiology of, 719–722
  pathophysiology of, 718–719
  treatment of, 722–727

Revascularization, for renovascular hypertension, 725–727

Risk factors and risk stratification, in hypertension, 541–558
  antihypertensive guidelines and, 549–552
  cardiovascular hazards, 547
  electrocardiography in, 545–546
  global risk assessment, 549–552
  J-curve controversy in, 544–545
  left ventricular hypertrophy and. See Left ventricular hypertrophy.
    misconceptions in, 542–543
    predisposing, 552–553
    prehypertension category in, 543–544
    preventive implications of, 552–553
    unrecognized myocardial infarction and, 546–547

Rosiglitazone, for cardiometabolic syndrome, 576

Salt intake, hypertension and, 532–535

SERCA2a receptor, in diastolic function, 651

Serine kinases, in oxidative stress, 575
Shear stress, cyclic, on arteries, 609
Sibutramine, for obesity, 744
Single-photon emission computed tomography
   in left ventricular hypertrophy, 643
   in myocardial ischemia, 687
Sleep apnea, obstructive, in obesity, 744
Smoking, hypertension and, 531–532
Sodium
   excretion of, renovascular hypertension and, 721–722
   restriction of
      for hypertension, in chronic kidney disease, 703
      in hypertension, 738–739
   retention of, in obesity, 735–736
Speckle tracking technology, in diastolic dysfunction, 656
Spironolactone, for hypertension, 689
   in cardiometabolic syndrome, 576
   in diastolic dysfunction, 652
   in heart failure prevention, 673–675
Stents, renal artery, 727
Stiffness, in arterial aging, 591–592, 599, 609–611, 653, 656
Stress echocardiography, in myocardial ischemia, 687
Stress electrocardiography, in myocardial ischemia, 686
Stroke, risk for, 547, 549
Strong Heart Study, 648, 666
Studies of Left Ventricular Dysfunction (SOLVD), 576, 672
Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalization in
   Seniors with Heart Failure study (SENIORS), 672, 674
Subfornical organ, reactive oxygen species effects on, 627
Superoxide
   in hypertension
      in kidney, 625–626
      vasculature and, 628
      in insulin resistance, 572–575
   structure of, 621
Superoxide dismutase
   action of, 623
   blood pressure reduction due to, 573–574
   in aging arteries, 589
   in hypertension, 623, 627
Survival and Ventricular Enlargement (SAVE) trial, 671–672
Sympathetic nervous system, activation of, in insulin resistance, 570
Syst-China trial, 611
Syst-Eur trial, 611
Systolic blood pressure, factors affecting, 606–609
Systolic dysfunction, 667
Systolic hypertension
   brachial pulse pressure in, 611–612
   cardiovascular disease prevention in, 614–615
   isolated, 544–545
      aging and, 598
      treatment guidelines for, 554–555
pulse wave reflections in, 607–608
treatment of, 656–657
Systolic Hypertension in Europe trial, 545
Systolic Hypertension in the Elderly Program (SHEP), 544–545

T

T lymphocytes, in atherosclerosis, 629–630
Target organs. See Cardiovascular disease; Heart; Kidney; Large arteries.
Telmisartan, for hypertension, in obesity, 742
Torsemide, for hypertension, 707
Trandolapril, for hypertension, 689, 742, 744
Trandolapril Cardiac Evaluation trial (TRACE), 671
Transforming growth factor
  angiotensin II interactions with, 562–563
  in arterial aging, 595–596
  obesity and, 736
Treatment of Obese Patients With Hypertension Study Group, 742
Treatment of Preserved Systolic Function Heart Failure with an Aldosterone Antagonist trial (TOPCAT), 658–659
Trial of Hypertension Prevention (TOPH), 534, 738
Trial of Nonpharmacological Interventions in the Elderly (TONE), 738
Tubuloglomerular feedback, in hypertension, 625

U

Ultrasonography
  in diastolic dysfunction, 654–655
  in left ventricular hypertrophy, 642
  in renovascular hypertension, 727–728
United States Carvedilol Heart Failure Study, 672, 674

V

Valsartan Heart Failure Trial, 671, 673
Valsartan in Acute Myocardial Infarction trial (VALIANT), 671
Valsartan in Diastolic Dysfunction trial (VALIDD), 649–650, 657–658
Vascular smooth muscle cells
  cyclic stress on, 609
  in aging arteries, 584–585, 608–609
  reactive oxygen species produced in, 572
Ventricle(s)
  coupling with aging arteries, 599–600
  filling pressure measurement, 654–656
  hypertrophy of. See Left ventricular hypertrophy.
  stiffness of, 653
Index

Verapamil, for hypertension, 689
   in chronic kidney disease, 708
   in obesity, 742, 744

W
Wall tension, in myocardial oxygen demand, 681–682
Weight loss, for obesity, 736–740, 744

X
Xanthine oxidase, in reactive oxygen species production, 572–573, 622